Drugs / SM04755
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03502434 | Sep → Nov 2017 | disease of the tendon | Biosplice Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03229291 | Nov 2016 → Jun 2017 | disease of the tendon | Biosplice Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02191761 | Jun 2014 → May 2015 | colorectal cancer, gastric cancer, liver cancer, malignant pancreatic neoplasm | Biosplice Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SM04755 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02191761 ↗ |
| Action | Inhibit | “SM04755 is a small molecule inhibitor of the Wnt pathway.” NCT03229291 ↗ |
| Modality | Small molecule | “SM04755 is a small molecule inhibitor of the Wnt pathway.” NCT03229291 ↗ |
| Route | Oral | “SM04755 administered orally” NCT02191761 ↗ |